Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting

by on May 25, 2023

Initial activity observed in combination therapy of one billion cells per dose with rituximab; majority of responses were observed in patients who had previously failed autologous CAR-T cell therapy AB-101 was well tolerated at up to four billion cells per dose as a monotherapy; up to 16 doses of AB-101 at one billion cells per…